Foundayo cuts sleep apnoea severity by up to 44% in phase 3, and Lilly plans a US filing
Lilly's 712-patient ATTAIN-OSA programme, presented at the American Heart Association meeting and published in JAMA, found Foundayo (orforglipron) reduced breathing interruptions by 43.8% at 52 weeks in people not using a CPAP machine and 27.5% in those who were. Around a third of non-CPAP patients reached remission or mild disease.
Lilly's 712-patient ATTAIN-OSA programme, presented at the American Heart Association meeting and published in JAMA, found Foundayo (orforglipron) reduced breathing interruptions by 43.8% at 52 weeks in people not using a CPAP machine and 27.5% in those who were. Around a third of non-CPAP patients reached remission or mild disease. Lilly plans to ask the FDA to add obstructive sleep apnoea to the label by the end of 2026, after filing for type 2 diabetes in September.
Source: Fierce Pharma (9 Nov 2026).